drugset / Trial / NCT00543491

MK0767 and Sulfonylurea Combination Study (0767-027)

NCT00543491

Phase 3 Terminated 129 enrolled Merck Sharp & Dohme LLC
RandomizedSingle-groupDouble-blindTreatment

Summary

This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Timeline

Start
2003-05
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MK0767 Small molecule